The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Dermatitis. 2010;21(1):59-60 ... NJ), and three different topical clotrimazole creams, with no improvement. Several vaginal potassium hydroxide and wet preparations had negative results.

Discover why analysts are bullish on Arcutis Biotherapeutics after strong Q3 results, despite recent market fluctuations in ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

The new PDUFA target date is March 12, 2025. The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Q) I’VE had a rash on my forehead for six months. For the first couple, I used a steroid cream but was then told not to any ...

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...